1. Dr. David Ribeiro, PhD Chief Executive Officer David.Ribeiro@proaxsis.com www.proaxsis.com @proaxsis

2. Respiratory diagnostics company 2  Commercialising immunoassay kits and Point-of-Care (POC) tests for management of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)  Patented proprietary ProteaseTag® technology for the capture, detection and measurement of active protease biomarkers – indicators of exacerbations  Launching POC tests in EU 2017  Series A funding for final validation of POC and pan-European launch

3. CF is a life-limiting inherited condition caused by a faulty gene Causes mucus to gather in the lungs and digestive system and creates a range of challenging symptoms 40,000 EU and 30,000 US Diagnosed 3

4. 19.9 million EU, 15.8 million US, 43 million China diagnosed 25% growth through 2033 COPD is an umbrella term used to describe progressive lung diseases Breathlessness, coughing, wheezing and chest tightness 4

5. Patented novel technology ProteaseTags™ Irreversibly capture a specific active protease Tools for the detection and quantification of the activity of a single protease species within a complex biological sample ProteaseTags™ Irreversibly capture a specific active protease Tools for the detection and quantification of the activity of a single protease species within a complex biological sample ProteaseTag ™ Technology: Novel and rapid method of detecting active protease biomarkers ProteaseTag ™ Technology: Novel and rapid method of detecting active protease biomarkers Applications Potential to be incorporated into a number of technology platforms Multi-analyte Product pipeline Applications Potential to be incorporated into a number of technology platforms Multi-analyte Product pipeline 5

6. NE is linked with exacerbation Moffitt et al, P102, British Thoracic Society, December 2015. NE measured in 20 matched sputum samples from COPD patients when stable and during exacerbation. * Sagel et al (2012) Am. J. Respir. Crit. Care Med., 186: p857-865. Sputum NE is the most informative biomarker to monitor disease activity* NE is also an effective biomarker to monitor decline in lung function 6

7. Research market – Immunoassay kits  Testing kit comprising of the necessary reagents to measure NE in lab  Recent kit sales to UK, Ireland, Germany, Switzerland and Sweden  CE Marking process initiated, submission target end Q2  Immunoassay accepted for use in a pharma company trial, and being validated by several others  Research collaborations with number of universities  Abstracts presented/accepted – ECFC, NACFC, BTS, ATS 7

8. Clinical market - Point-of-care NEATstik Launch Strategy  CE mark  Launch first as general IVD for use in clinic – elevate clinician awareness  Follow-up launch as point-of-care IVD for use by the patient at home Business Model  Western/Northern Europe: Direct sales  Rest of Europe/Asia/US: Seek commercial partners Reimbursement Strategy  Health economic model prepared for launch, using third party provider 8

9. Series A fundraising Use of Proceeds  Complete NEATstik POC development programme and CE marking  Build commercial team and launch across Europe  Establish base sales in key EU markets  Ongoing development and launch of further respiratory protease target assays  Prospective pan-European COPD trial Funding plans 9

10. Product pipeline 10 Proteases in disease AIDS (Resistant HIV protease) Alzheimer's (β and γ-secretases) Pulmonary embolsim (Thrombin, Fxa) Heart attack (Thrombin, Fxa) Stroke (Thrombin, Fxa) Asthma (Tryptase) Neurodegenerative disorders (Caspases) Cancer (Cathepsins) Osteoporosis (Cathepsins) COPD (Cathepsins) Hepatitis C (Hep. C protease) ARDS (Neutrophil elastase) Diabetes (DPP IV) Arthritis/Inflammation (TACE, MMPs) Hypertension (ACE/NEP/ECE) Angioedema Kallikrien Cystic fibrosis/COPD (Neutrophil elastase)

11. Experts in diagnostics & respiratory disease Dr. David Ribeiro – CEO Senior management at Pfizer, Solvay Healthcare and Encysive Pharma. Most recently, at Pharmaxis, worked on a diagnostic test for assessing bronchial hyper-­responsiveness in asthma, and a therapeutic product designed for the chronic treatment of patients with CF Prof. Brain Walker – CSO 30 years of experience in the design and synthesis of “Protease-Tags”. Chair of Biomedicinal Chemistry – School of Pharmacy QUB. World renowned thought leader in respiratory disease Sarah Ganniclefft – Sales and Marketing Manager Significant managerial sales and marketing experience in diagnostics at BD and Roche 11

12. Dr. David Ribeiro, PhD Chief Executive Officer David.Ribeiro@proaxsis.com www.proaxsis.com @proaxsis